Condition: Adult Glioblastoma · High Grade Glioma · WHO Grade III or IV Malignant Glioma · Sponsor: University of Florida
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in (Stratum 1) adult patients with newly diagnosed GBM (MGMT low level or unmethylated in adults only) and (Stratum 2) in pediatric patients with newly diagnosed HGG (pHGG). Funding Source - FDA OOPD
This description comes directly from the study's public registry record.
Marcia Hodik · 352-273-5519 · wells-BTC@ufl.edu
Always discuss trial participation with your own doctor first.
| Children's National Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| UF Health | Gainesville, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04573140